 | Up a level |
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445